Zacks Research Analysts Reduce Earnings Estimates for PBH

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Stock analysts at Zacks Research decreased their Q1 2027 EPS estimates for shares of Prestige Consumer Healthcare in a report released on Monday, June 16th. Zacks Research analyst R. Department now anticipates that the company will earn $1.25 per share for the quarter, down from their prior forecast of $1.26. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q3 2027 earnings at $1.29 EPS.

Several other analysts also recently weighed in on the stock. Wall Street Zen raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, May 17th. Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a “hold” rating in a research note on Thursday, May 8th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare has an average rating of “Moderate Buy” and an average target price of $93.33.

Prestige Consumer Healthcare Stock Down 0.3%

Shares of Prestige Consumer Healthcare stock opened at $83.37 on Thursday. The company has a market cap of $4.12 billion, a P/E ratio of 19.43, a PEG ratio of 2.51 and a beta of 0.45. The firm has a fifty day moving average of $83.93 and a two-hundred day moving average of $82.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.82 and a current ratio of 4.20. Prestige Consumer Healthcare has a one year low of $64.94 and a one year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.02. The firm had revenue of $296.52 million during the quarter, compared to analysts’ expectations of $289.36 million. Prestige Consumer Healthcare had a net margin of 18.86% and a return on equity of 12.87%. Prestige Consumer Healthcare’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.02 EPS.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Institutional investors have recently bought and sold shares of the business. Kestra Investment Management LLC purchased a new stake in Prestige Consumer Healthcare during the fourth quarter worth approximately $27,000. Opal Wealth Advisors LLC purchased a new stake in Prestige Consumer Healthcare during the first quarter worth approximately $38,000. CIBC Private Wealth Group LLC grew its stake in Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock worth $34,000 after buying an additional 152 shares during the period. Headlands Technologies LLC purchased a new stake in Prestige Consumer Healthcare during the fourth quarter worth approximately $40,000. Finally, Geneos Wealth Management Inc. grew its stake in Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after buying an additional 269 shares during the period. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.